{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05111977",
            "orgStudyIdInfo": {
                "id": "R01MH127225",
                "type": "NIH",
                "link": "https://reporter.nih.gov/quickSearch/R01MH127225"
            },
            "organization": {
                "fullName": "Laureate Institute for Brain Research, Inc.",
                "class": "OTHER"
            },
            "briefTitle": "Gastrointestinal Interoception in Anorexia Nervosa",
            "officialTitle": "A Neurocomputational Assay of Gastrointestinal Interoception in Anorexia Nervosa",
            "therapeuticArea": [
                "Other"
            ],
            "study": "gastrointestinal-interoception-in-anorexia-nervosa"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-04-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-07-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-10-19",
            "studyFirstSubmitQcDate": "2021-10-27",
            "studyFirstPostDateStruct": {
                "date": "2021-11-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Laureate Institute for Brain Research, Inc.",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "Anorexia nervosa (AN) has among the highest mortality rate of any psychiatric illness, yet we have a poor understanding of the biological causes of this disorder. In this study, we use a novel mechanosensory intervention to examine the basic question of whether individuals with AN have abnormal \"gut sensations\" and whether such indicators are associated with adverse consequences from the disorder."
        },
        "conditionsModule": {
            "conditions": [
                "Anorexia Nervosa"
            ],
            "keywords": [
                "Interoception"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "whoMasked": [
                        "PARTICIPANT"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Capsule stimulation",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in this arm will receive gastric stimulation via the Vibrant capsule",
                    "interventionNames": [
                        "Device: Vibrant capsule"
                    ]
                },
                {
                    "label": "Placebo stimulation",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants in this arm will receive no gastric stimulation via a placebo capsule",
                    "interventionNames": [
                        "Device: Vibrant capsule"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "Vibrant capsule",
                    "description": "A capsule delivering mechanical vibrations",
                    "armGroupLabels": [
                        "Capsule stimulation",
                        "Placebo stimulation"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Interoceptive precision",
                    "description": "Interoceptive sensory precision",
                    "timeFrame": "At baseline"
                },
                {
                    "measure": "Interoceptive prior",
                    "description": "Interoceptive prior expectaiton",
                    "timeFrame": "At baseline"
                },
                {
                    "measure": "Learning rate",
                    "description": "Interoceptive learning rate",
                    "timeFrame": "At baseline"
                },
                {
                    "measure": "Evoked response potential",
                    "description": "Electroencephalogram (EEG) evoked response amplitude within 700 millisecond period following vibration onset",
                    "timeFrame": "At baseline"
                },
                {
                    "measure": "Electrogastrogram",
                    "description": "Stomach electrogastrogram (EGG) power in bradygastria, normogastria, tachygastria and total power bands",
                    "timeFrame": "At baseline"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Normalized A prime",
                    "description": "Signal detection accuracy measure",
                    "timeFrame": "At baseline"
                },
                {
                    "measure": "Illness status",
                    "description": "Relapse, remission, or recovery status",
                    "timeFrame": "At 1 month, 3 month, and 6 month follow-up"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nHC Inclusion criteria:\n\ni. Body mass index \u2265 18.5. ii. Females, ages 15 to 40 years iii. Women of childbearing age: a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study.\n\niv. Independently ambulatory v. Possession of a smartphone with data plan vi. English proficiency vii. Willingness and ability to participate in study procedures viii. Provision of signed and dated informed consent form\n\nAN Inclusion criteria:\n\ni. Primary clinical diagnosis of anorexia nervosa as defined by Laureate Eating Disorders Program ii. Body mass index \u2265 18.5. iii. Transitioned from acute clinical status rating to residential clinical status or partial/intensive outpatient clinical status rating iv. No new medication prescription in the week prior to study randomization, Must be on a stable dose of medication for at least 1 week.\n\nv. Females, ages 15 to 40 years vi. Women of childbearing age: a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study.\n\nvii. Independently ambulatory viii. Possession of a smartphone with data plan ix. English proficiency x. Willingness and ability to participate in study procedures xi. Provision of signed and dated informed consent form\n\nExclusion Criteria:\n\nHC Exclusion criteria:\n\ni. Current diagnosis of a psychiatric disorder per the MINI International Diagnostic Interview\n\nii. Taking any psychotropic medication\n\niii. Active suicidal ideation with intent or plan\n\niv. Active cutting or skin lacerating behaviors\n\nv. Active purging behaviors (specifically, self-induced vomiting), and/or a history of severe self-induced vomiting\n\nvi. Pregnancy as defined by a urine screen during screening, and confirmed during each stimulation visit, and must not be lactating\n\nvii. History of significant gastrointestinal disorder, including any form of inflammatory bowel disease or gastrointestinal malignancy (celiac disease is accepted if the subject has been treated and is in remission)\n\nviii. History of complicated/obstructive diverticular disease\n\nix. Clinical evidence of significant gastroparesis\n\nx. Diagnosis of mega-rectum or colon, congenital anorectal malformation, or clinically significant rectocele or rectal prolapse\n\nxi. History of intestinal or colonic obstruction, or suspected intestinal obstruction\n\nxii. History of intestinal resection (with an exception for appendectomy, cholecystectomy and inguinal hernia repair), history of bariatric surgery or evidence of any structural abnormality of the gastrointestinal tract that might affect transit\n\nxiii. History of Zenker's diverticulum, dysphagia, Barrett's esophagus, esophageal stricture or achalasia, transesophageal fistula, or eosinophilic esophagitis.\n\nxiv. Clinical evidence (as judged by the investigator) of respiratory, cardiovascular, renal, hepatic, biliary, endocrine, or neurologic disease\n\nxv. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs): chronic use is defined as taking full dose NSAIDs more than three times a week for at least six months. Subjects on cardiac doses of aspirin may be enrolled in the study\n\nxvi. Cardiac pacemaker, implantable cardioverter defibrillator, implantable infusion device, or gastric electrical stimulator\n\nxxv. Orthostatic hypotension (defined as a drop of \u2265 20 mm Hg in systolic BP or a drop of \u2265 10 mm Hg in diastolic BP when measured shortly after transitioning from lying down to standing)\n\nxxvi. Any other condition which in the opinion of the investigator may adversely affect the safety of the subject or would limit the subject's ability to complete the study\n\nxxvii. No smartphone/computer or limited access to a smartphone/computer\n\nxxviii. Regular use of any of the following medications or procedures: Medications that may substantially affect intestinal motility, prokinetics at high doses (metoclopramide, erythromycin, senna, prucalopride), anti-Parkinsonian medications, opiates, opioids, calcium-channel blockers, enemas\n\nxxix. History of a GI bleed within the last 3 months\n\nxxx. Pelvic floor dysfunction/defecatory disorder, based on subject history\n\nxxxi. Planning to undergo MRI during study time frame\n\nxxxii. Any known allergy to soybean or beeswax or Calcium Carbonate\n\nxxxiii. Bradycardia less than 40 beats per minute\n\nxxxiv. Pain Disorder\n\nAN Exclusion criteria:\n\ni. Active suicidal ideation with intent or plan\n\nii. Active cutting or skin lacerating behaviors\n\niii. Active purging behviors (specifically, self-induced vomiting), and/or a history of severe self-induced vomiting\n\niv. Pregnancy as defined by a urine screen during screening, and confirmed during each stimulation visit, and must not be lactating\n\nv. History of significant gastrointestinal disorder, including any form of inflammatory bowel disease or gastrointestinal malignancy (celiac disease is accepted if the subject has been treated and is in remission)\n\nvi. History of complicated/obstructive diverticular disease\n\nvii. Clinical evidence of significant gastroparesis\n\nviii. Diagnosis of mega-rectum or colon, congenital anorectal malformation, or clinically significant rectocele or rectal prolapse\n\nix. History of intestinal or colonic obstruction, or suspected intestinal obstruction\n\nx. History of intestinal resection (with an exception for appendectomy, cholecystectomy and inguinal hernia repair), history of bariatric surgery or evidence of any structural abnormality of the gastrointestinal tract that might affect transit\n\nxi. History of Zenker's diverticulum, dysphagia, Barrett's esophagus, esophageal stricture or achalasia, transesophageal fistula, or eosinophilic esophagitis.\n\nxii. Clinical evidence (as judged by the investigator) of respiratory, cardiovascular, renal, hepatic, biliary, endocrine, or neurologic disease\n\nxiii. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs): chronic use is defined as taking full dose NSAIDs more than three times a week for at least six months. Subjects on cardiac doses of aspirin may be enrolled in the study\n\nxiv. Cardiac pacemaker, implantable cardioverter defibrillator, implantable infusion device, or gastric electrical stimulator\n\nxv. Orthostatic hypotension (defined as a drop of \u2265 20 mm Hg in systolic BP or a drop of \u2265 10 mm Hg in diastolic BP when measured shortly after transitioning from lying down to standing)\n\nxvi. Any other condition which in the opinion of the investigator may adversely affect the safety of the subject or would limit the subject's ability to complete the study\n\nxvii. No smartphone/computer or limited access to a smartphone/computer\n\nxviii. Regular use of any of the following medications or procedures: Medications that may substantially affect intestinal motility, prokinetics at high doses (metoclopramide, erythromycin, senna, prucalopride), anti-Parkinsonian medications, opiates, opioids, calcium-channel blockers, enemas\n\nxix. History of GI bleed within the last 3 months\n\nxx. Pelvic floor dysfunction/defecatory disorder, based on subject history\n\nxxi. Planning to undergo MRI during study time frame\n\nxxii. Any known allergy to soybean or beeswax, or Calcium Carbonate\n\nxxiii. Bradycardia less than 40 beats per minute\n\nxxiv. Pain Disorder",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "minimumAge": "15 Years",
            "maximumAge": "40 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jaimee Bruce, BSN",
                    "role": "CONTACT",
                    "phone": "9185025145",
                    "email": "JBruce@laureateinstitute.org"
                },
                {
                    "name": "Sahib Khalsa, MD",
                    "role": "CONTACT",
                    "phone": "9185025743",
                    "email": "skhalsa@laureateinstitute.org"
                }
            ],
            "locations": [
                {
                    "facility": "Laureate Institute for Brain Research",
                    "status": "RECRUITING",
                    "city": "Tulsa",
                    "state": "Oklahoma",
                    "zip": "47136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Colleen McCallum, MBA",
                            "role": "CONTACT",
                            "email": "cmccallum@laureateinstitute.org"
                        },
                        {
                            "name": "Sahib S Khalsa, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.15398,
                        "lon": -95.99277
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "We will upload the collected data via the NIMH Data Archive (NDA) data repository.",
            "timeFrame": "Data will be available approximately one year after the end of the study period."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000855",
                    "term": "Anorexia"
                },
                {
                    "id": "D000000856",
                    "term": "Anorexia Nervosa"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012817",
                    "term": "Signs and Symptoms, Digestive"
                },
                {
                    "id": "D000001068",
                    "term": "Feeding and Eating Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4181",
                    "name": "Anorexia",
                    "asFound": "Anorexia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4182",
                    "name": "Anorexia Nervosa",
                    "asFound": "Anorexia Nervosa",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15622",
                    "name": "Signs and Symptoms, Digestive",
                    "relevance": "LOW"
                },
                {
                    "id": "M4380",
                    "name": "Feeding and Eating Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                }
            ]
        }
    },
    "hasResults": false
}